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Abstract: The aim of this study was to assess the cost-effectiveness, from a health care 
perspective, of adding rituximab to fludarabine and cyclophosphamide scheme (FCR versus 
FC) for treatment-naïve and refractory/relapsed Ukrainian patients with chronic lymphocytic 
leukemia. A decision-analytic Markov cohort model with three health states and 1-month cycle 
time was developed and run within a life time horizon. Data from two multinational, prospective, 
open-label Phase 3 studies were used to assess patients’ survival. While utilities were generalized 
from UK data, local resource utilization and disease-associated treatment, hospitalization, and 
side effect costs were applied. The alternative scenario was performed to assess the impact of 
lower life expectancy of the general population in Ukraine on the incremental cost-effectiveness 
ratio (ICER) for treatment-naïve patients. One-way, two-way, and probabilistic sensitivity analy-
ses were conducted to assess the robustness of the results. The ICER (in US dollars) of treating 
chronic lymphocytic leukemia patients with FCR versus FC is US$8,704 per quality-adjusted life 
year gained for treatment-naïve patients and US$11,056 for refractory/relapsed patients. When 
survival data were modified to the lower life expectancy of the general population in Ukraine, the 
ICER for treatment-naïve patients was higher than US$13,000. This value is higher than three 
times the current gross domestic product per capita in Ukraine. Sensitivity analyses have shown 
a high impact of rituximab costs and a moderate impact of differences in utilities on the ICER. 
Furthermore, probabilistic sensitivity analyses have shown that for refractory/relapsed patients 
the probability of FCR being cost-effective is higher than for treatment-naïve patients and is 
close to one if the threshold is higher than US$15,000. State coverage of rituximab treatment 
may be considered a cost-effective treatment for the Ukrainian population under conditions of 
economic stability, cost-effectiveness threshold growth, or rituximab price negotiations.
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Introduction
Chronic lymphocytic leukemia (CLL) is a progressive oncological disease character-
ized by the clonal proliferation and accumulation of neoplastic B lymphocytes in the 
blood, bone marrow, lymph nodes, and spleen. According to the Ukrainian National 
Cancer Register1 the total morbidity rate for patients with diagnosed leukemia was 
7.8 per 100,000 people. No national Ukrainian statistical data on CLL prevalence 
are available; however, if we assume the same distribution as in the US exists for 
the four major types of leukemia, up to 3.7 per 100,000 people are estimated to be 
CLL related.2 The clinical course of this disease can be highly diverse and dependent 
on many factors, such as stage of the disease by Rai (from 0 to IV) and Binet (from 
A to C), chromosomal abnormalities, or mutations of the immunoglobulin heavy 
 variable chain gene.3–5
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With the exception of blood band marrow transplantation – 
which has significant limitations by age and comorbidities – 
CLL remains an incurable condition. According to the national 
treatment protocol in Ukraine5 there is a number of treatment 
options for CLL patients. Besides the “watch and wait” 
strategy for patients with the asymptomatic state of CLL, 
monotherapies are currently available: cytotoxic drugs 
including alkylating agents (chlorambucil, cyclophosph-
amide, and bendamustine), antimetabolites or purine analogs 
(fludarabine or cladribine), mitoxantrone (an anthracycline) 
and prednisolone (a corticosteroid), as well as a number of 
therapeutic chemotherapy combination schemes.3,5 One of 
the most frequently prescribed schemes for CLL patients 
treated in specialized hospitals of Ukraine is a fludarabine 
and cyclophosphamide scheme (FC).6
Rituximab, a monoclonal antibody that targets the CD20 
cell surface antigen, is recommended for use in combina-
tion with chemotherapy for both treatment-naïve patients, 
refractory patients (those who experienced treatment failure 
or disease progress within 6 months of the last treatment) or 
patients who relapsed (those who experienced a response 
to therapy, but progressed after 6 or more months). Despite 
being one of the most expensive drugs used in CLL treat-
ment in Ukraine, rituximab was included in the state tender 
purchases the previous years.6,7 Adding rituximab to FC 
(FCR) has been shown to be a promising medical product 
according to clinical trial data on both previously treated and 
untreated CLL patients.4,8
The cost-effectiveness of FCR versus FC in treatment 
of naïve or refractory/relapsed patients was previously 
confirmed in Spain, the US, and the UK.9–11 In Spain the 
incremental cost-effectiveness ratio (ICER) was €19,343 per 
quality-adjusted life year (QALY) gained for the first-line 
treatment and €24,781 for the second-line treatment over a 
10-year horizon.9 In the US study the ICER was US$23,530 
per QALY considering a third-party payer and US$31,513 per 
QALY considering a societal perspective over the life time 
horizon.10 In the UK rituximab was also considered to be a 
cost-effective option with an ICER of £13,189 per QALY for 
FCR versus FC in the treatment of naïve patient population; 
however its combination with other chemotherapy agents 
was not recommended by the National Institute for Health 
and Care Excellence.11
To the best of our knowledge no economic evaluation 
on rituximab use was performed in Ukraine, nor any other 
country of the Central and Eastern European or former 
Soviet region. Because of differences in treatment practice, 
perspectives, unit costs (including hospitalization), and 
demographic characteristics (both patients and general 
population), generalizability to Ukraine of the economic 
evaluations mentioned above is not possible. While no cost-
effectiveness threshold has been established in Ukraine, the 
World Health Organization (WHO) considers technologies 
with a threshold of less than one GDP per capita to be very 
cost-effective, and those with a threshold of less than three 
GDP per capita to be cost-effective.12 In 2013 the GDP per 
capita in Ukraine was equal to US$3,900, according to data 
of the World Bank.13
In sum, the aim of this study was to assess, from a 
health care perspective using a life time horizon, the cost-
effectiveness of FCR compared to FC for treatment-naïve 
and refractory/relapsed Ukrainian CLL patients.
Methods
Framework/structure of the model
Two decision-analytic Markov cohort models with the same 
structure were developed in Microsoft® Excel 2007 to assess 
the incremental costs and benefits associated with FCR. 
These models were run on two populations using data from 
two randomized controlled trials, one with treatment-naïve 
and one with refractory/relapsed patients. Three health states 
were defined in the models with a cycle time of 1 month: 
1) stable or progression-free state; 2) disease-progressed 
state; and 3) death. Assessment of the incremental costs and 
benefits from a health care perspective was conducted using 
a life time horizon. QALYs comprised the main outcome 
in both models with uniform 3% discounting for both costs 
and effects.14
Target population
We considered the modeled cohort of treatment-naïve 
patients to be identical to the trial population from a pub-
lished prospective, open-label, Phase 3 study on 817 ran-
domly assigned (1:1) patients carried out in 190 centers in 
eleven countries. Enrolled in this study were treatment-naïve 
patients diagnosed with immunophenotypically confirmed 
CLL in Binet stage C (31% in FC and 31% in FCR) or those 
with confirmed active disease in Binet stages A (5% in FC 
and 4% in FCR) or B (63% in FC and 64% in FCR). Mean 
age of patients was 61 years and 74% were males. Eastern 
Cooperative Oncology Group (ECOG) performance status 
of 0 was reported in 58% of FC and 56% of FCR groups.4 
(ECOG performance status is the criteria used to assess 
how the disease affects daily living abilities of patients, 
where “0” is a fully active person and “5” is dead [http://
www.ecog.org/]).
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The modeled cohort of refractory/relapsed patients was 
considered to be identical to the trial population from an 
international, multicenter, open-label, Phase 3 study on 552 
randomly assigned (1:1) patients carried out in 88 centers 
in 17 countries. Patients who had received one prior line of 
therapy, such as single-agent chlorambucil (or combined 
with prednisone/prednisolone), single-agent fludarabine 
(or another nucleoside analog), or an alkylator containing 
combination regimen, but not an alkylator/nucleoside analog 
combination, were enrolled in that study. The distribution 
of CLL patients by confirmed Binet stages in this trial was 
as follows: stage C (31% in FC and 31% in FCR), stage A 
(11% in FC and 9% in FCR), and stage B (58% in FC and 
60% in FCR). Mean age of patients was 62 years in FC and 
63 in FCR groups, 66% (FC) and 68% (FCR) were males. 
An ECOG performance status of 0 was reported in 59% of 
FC and 61% of FCR groups.8
Treatment and treatment effect
According to trial data4,8 and national clinical guidelines, CLL 
patients on FCR should receive the following doses of drugs 
during each cycle: fludarabine (25 mg/m2/d), cyclophos-
phamide (250 mg/m2/d) for 3 days, rituximab (375 mg/m2 
on day one of the first cycle and 500 mg/m2 on day one of 
subsequent cycles). In the model, dose-per-patient was cal-
culated using an average body surface among the Ukrainian 
population (1.86 m2). We considered that the Markov cohort 
population did not receive full courses of therapy similar to 
the trial population,4,8 so the final average doses of each drug 
were adjusted to the average consumed doses (by treatment 
adherence in trials) (Table 1).
survival data
Overall survival and progression-free survival (PFS) were 
retrieved from the trials’ publications presenting Kaplan–Meier 
plots.4,8 The reported observation period equal to 61 months for 
treatment-naïve patients and to 57 months for previously-treated 
patient (52 months for PFS during FC treatment) was chosen.4,8 
There was no information available on characteristics of Ukrai-
nian CLL patients by Binet stages and ECOG performance 
status. At the same time, by sex and age distribution Ukrainian 
CLL patients were similar to trial populations selected as clini-
cal data sources.4,6,8 Two parametric extrapolation methods were 
applied. A Weibull model was selected to incorporate mono-
tonic hazards, while a log-logistic model was selected as an 
alternative to incorporate non-monotonic hazards. The model 
that provides the closest parametric estimation was selected for 
cohort survival assessment.
Costs
In line with recommendations of the International Society 
For Pharmacoeconomics and Outcomes Research taskforce 
report on transferability,15 unit costs and resource utiliza-
tion were retrieved from local sources. From the health care 
perspective, the following costs were included in the model: 
initial therapy costs, hospitalization costs, adverse events 
costs, and salvage costs (Table 1). Unit drug costs were 
included in the deterministic model by the most frequently 
prescribed trade names.6 Unit drug prices were retrieved from 
the website of Ukraine’s Ministry of Health.16 Costs of grades 
3 and 4 adverse events reported with a frequency greater than 
or equal to 5% were accounted for in the model calculations. 
Opinions of clinical experts from specialized institutions of 
Ukraine and hospital records were used to define the most 
frequently prescribed treatment schemes for these condi-
tions A previously published costing study in Ukraine was 
used to assess costs of salvage treatment.6 Because of data 
obsolescence, these costs were considered to grow by the 
consumer price index for pharmaceuticals and health care 
for the last 4 years (5.7%). Additionally, the model took into 
consideration the monthly growth in costs for salvage treat-
ment proportional to an average monthly consumer price 
index for pharmaceuticals and health care (0.11875%).17 Data 
of specialized hospitals in Ukraine were used to determine 
an average duration of hospitalization due to a relapse, as 
well as daily costs of hospital stay excluding pharmaceutical 
treatment.6 Similar to pharmaceutical treatments, hospital 
stay unit costs were considered to grow proportionally to an 
average consumer price index for pharmaceuticals and health 
care. The exchange rate of the National Bank of Ukraine on 
June 4, 2014 (11,833 Ukrainian Hryvnia per US$) was used 
in all calculations.
Utilities
No country-specific utility data were available for CLL 
patients, nor for the general Ukrainian population, there-
fore, utilities of health states associated with CLL treatment 
 (values of 0.78 for the progression-free or stable disease state 
and 0.68 for the progressed disease) were assumed generaliz-
able from the UK.18
Sensitivity analyses and data 
transferability
We used sensitivity analyses to address uncertainty in the 
defined input parameters specific for Ukraine and those 
generalized from other populations. Using univariate analy-
ses we assessed the impact of variations in rituximab costs, 
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uncertainty of the model. Both deterministic and probabilistic 
model parameters are presented in Table 1.
Results
Treatment with rituximab resulted in both a longer expected 
survival and a gain in QALYs compared to the standard ther-
apy (Table 2). The gain in expected number of life years was 
1.60 for both treatment-naïve and refractory/relapsed patients 
treated with the FCR versus FC in the base-case scenario. 
Associated costs were higher with FCR rather than FC treat-
ment in the base case and all alternative scenarios (Table 2). 
The difference in QALYs gained and costs was smaller in 
the scenarios where survival analysis was conducted on the 
trial data with the longer follow-up (and the opposite). When 
survival data on treatment-naïve patients were extrapolated 
to 65 months, the incremental value of QALYs became nega-
tive. There was a smaller observed difference in both QALYs 
and costs for the FC and FCR treatment-naïve population, 
when adjustment to the expected higher mortality among the 
general population of Ukraine was conducted.
For every expected QALY gained, US$8,704 will be 
needed in the base-case scenario for state coverage of 
treatment-naïve patients, which can be considered a cost-
effective option. The ICER of treating refractory/relapsed 
patients with FCR is close to the cost-effectiveness threshold 
within the base-case scenario (ICER US$11,056; threshold of 
three GDP per capita is US$11,700). The ICER of FCR use 
for treatment-naïve patients will be close to US$13,000 if a 
higher mortality among the general population in Ukraine is 
considered in the survival analysis. This ICER for treatment-
naïve patients is above the theoretical cost-effectiveness 
threshold in Ukraine.
As can be seen from Table 3, an increase in the average 
consumer price index and discount rate caused a higher 
 hospitalization costs, salvage treatment costs, costs of side 
effects, average monthly index of consumption prices and 
discount rates. Multivariate analysis was applied because 
the UK data on utilities for different cancer states were 
generalized to the Ukrainian population for whom local 
data was absent.
The two trials used a multinational sample as a source of 
survival data for Markov cohort CLL patients.4,8 Although 
the patient’s country of enrollment in the trials was not 
reported, we assume that most were enrolled in countries 
with developed economies, where life-duration of the gen-
eral population differs from those in Ukraine. Therefore we 
report an alternative scenario with Ukraine-specific mortality 
rate for non-CLL related causes to assess the impact of this 
parameter on the ICER. For this the sex- and age-specific 
difference in death probability among general population in 
the US and Ukraine was calculated. For this the difference 
in death probabilities between US and Ukrainian males and 
females of different age was calculated first using national 
statistical data.19,20 Afterward, the death probability among 
the population identical to the cohort by sex and age charac-
teristics was retrieved. As the next step the overall survival 
and PFS from the trial were added to the positive or negative 
coefficient of the difference in mortality depending on the 
patient’s age at initiation of therapy. The survival analysis 
with Weibull extrapolation was performed on the received 
adjusted data to ensure higher reliability of the received 
results.
Additional scenario analyses were conducted to assess the 
impact of survival analysis on cost-effectiveness results. We 
varied duration of patients’ observation period in the trials and 
assessed impact of these changes on the results of survival 
analysis and economic evaluations. Probabilistic sensitivity 
analyses with 5,000 runs were conducted to define overall 
Table 2 Cost-effectiveness analysis of adding rituximab to fludarabine plus cyclophosphamide scheme in treatment-naïve and refractory/
relapsed patients: base-case and scenario analyses
Cost difference QALY difference ICER (US$/QALY)
Treatment-naïve patients
Base-case scenario FCR versus FC US$10,827 1.24 US$8,704
Scenario 1: Ukraine-specific mortality among general population US$8,022 0.62 US$12,897
scenario 2: 56 months survival data US$16,881 2.61 US$6,475
scenario 3: 60 months survival data US$15,204 2.22 US$6,851
scenario 4: 62 months survival data US$7,677 0.62 US$12,343
scenario 5: 65 months extrapolated survival data US$4,786 -0.83 Dominated
Treatment-experienced patients
Base-case scenario FCR versus FC US$13,081 1.18 US$11,065
Scenario 1: 52 months survival data, ICER (US$ per QALY) US$ 14,660 1,53 US$9,557
Abbreviations: FC, fludarabine and cyclophosphamide scheme; FCR, rituximab with fludarabine and cyclophosphamide scheme; QALY, quality-adjusted life year; ICER, 
incremental cost-effectiveness ratio.
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Table 3 Univariate and multivariate sensitivity analysis: impact of costs variations on cost-effectiveness results
Parameters of variation and values ICER treatment-naïve  
patients
ICER treatment-experienced 
patients
US$/QALY % of change  
from base ICER
US$/QALY % of change  
from base ICER
Average monthly index of consumption prices
0% US$8,501 2% US$10,677 4%
0.2375% (double from deterministic value) US$8,907 -2% US$11,453 -4%
Discounting, annual
0% US$6,904 21% US$8,754 21%
5% US$10,194 -17% US$13,010 -18%
10% US$15,041 -73% US$19,494 -76%
Multivariate (discounting and average monthly index of consumption prices)
0% US$6,645 24% US$8,297 25%
Doubled from deterministic value US$11,184 -28% US$14,440 -31%
Rituximab costs
50% from deterministic costs US$4,538 48% US$6,471 42%
25% from deterministic costs US$2,455 72% US$4,173 62%
120% from deterministic costs US$10,371 -19% US$12,903 -17%
Hospitalization costs
50% from deterministic costs US$8,673 0% US$10,895 2%
25% from deterministic costs US$8,657 1% US$10,810 2%
120% from deterministic costs US$8,717 0% US$11,133 -1%
Salvage therapy costs
50% from deterministic costs US$8,563 2% US$10,298 7%
25% from deterministic costs US$8,492 2% US$9,914 10%
120% from deterministic costs US$8,761 -1% US$11,372 -3%
Side effects costs (FCR)
50% from deterministic costs US$8,662 0% US$11,036 0%
25% from deterministic costs US$8,640 1% US$11,022 0%
120% from deterministic costs US$8,722 0% US$11,076 0%
Utilities
Utility score 0.78 for progressed state  
and 0.88 for progression-free state
US$7,710 11% US$9,744 12%
Utility score 0.58 for progressed state  
and 0.68 for progression-free state
US$9,993 -15% US$12,800 -16%
Utility score 0.58 for progressed state  
and 0.88 for progression-free state
US$7,786 11% US$10,838 2%
Abbreviations: FCR, rituximab with fludarabine and cyclophosphamide scheme; QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio.
ICER for both treatment-naïve and refractory/relapsed 
patient populations. Similarly, multivariate analyses with 
zero values for both discounting and average monthly index 
of consumer prices resulted in ICERs of US$6,645 and 
US$8,297, respectively. Rituximab cost was the only cost 
parameter having a significant impact on the ICER in both 
populations. Changes in utilities had a moderate impact on 
cost-effectiveness results.
The results of probabilistic sensitivity analysis showed a 
high probability for FCR treatment to be cost-effective for 
both treatment-naïve patients (cost difference US$13,118, 
standard deviation [SD] US$8,079; QALYs difference 2.21, 
SD 1.78; ICER US$5,938) and refractory/relapsed patients 
(cost difference US$14,290, SD US$2,455; QALYs differ-
ence 1.68, SD 0.45; ICER US$8,485) with the threshold of 
US$11,000 (Figure 1). As the threshold value increases, the 
probability of FCR being cost-effective is higher for refrac-
tory/relapsed patients. In particular, when the threshold is 
higher than US$15,000, the probability of FCR being cost-
effective converges to one for refractory/relapsed patients 
and to 0.80 for treatment-naïve patients (Figure 2).
Discussion
Neither for treatment-naïve nor for refractory patients is FCR 
a cost-effective option when using a threshold of US$3,900.13 
However, use of FCR can still be considered a cost-effective 
option when using the theoretical threshold of three times the 
GDP per capita in Ukraine. As such, we conclude that provid-
ing this drug should not be considered the highest priority, 
but should depend on budget availability. This conclusion 
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Abbreviation: FCR, rituximab with fludarabine and cyclophosphamide scheme.
is supported by the decision uncertainty demonstrated by 
the sensitivity analyses; thus, the state coverage of this drug 
for both treatment-naïve and refractory/relapsed population 
remains a possibility to be argued.
The Ukrainian Ministry of Health purchases rituximab 
annually for CLL patients’ needs without recommendations 
on its actual use. Nearly US$1.4 million of the state budget 
was spent on rituximab purchase in 2013.7 However, based 
on current evidence there is a higher rationality for it to be 
provided for the treatment-naïve patient population, rather 
than for refractory/relapsed patients. At the same time, if the 
theoretical threshold will become higher as a result of an 
improving Ukrainian economy, then coverage of refractory/
relapsed patients is likely to become a more cost-effective 
option than that for the treatment-naïve population, an out-
come primarily related to the higher stability of the results. 
On the other hand, in an unstable economic environment, 
FCR treatment of refractory/relapsed patients may not be a 
cost-effective option from a health care perspective, taking 
into account that any increase in the discount rate, treatment 
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costs, or inflation rate (index of consumer prices) leads to an 
ICER estimate close to or above the value of the theoretical 
threshold. Because rituximab cost was the most influential 
parameter, price negotiation may be applied to ensure that 
state spending on this treatment is rational.
Because multinational clinical data were used for both 
models, we were concerned with how representative the trial 
population would be for Ukraine. While published data were 
used to populate the models, the cohort population in both 
models was not different by sex and age characteristics from 
both trial population and profiles of CLL patients in Ukraine in 
terms of mean age of naïve patients (60.3), age of refractory/
relapsed patient (62.8), and the fact that 67% of patients were 
male.6 Moreover, we considered that because of differences in 
age at diagnosis between different countries, if trial data were 
primarily retrieved from economically developed countries, 
the mortality from other causes in CLL trial population may 
be different from those in Ukraine. We conclude that if such 
a case exists, then it is doubtful that the use of rituximab in 
CLL population in Ukraine will be cost-effective.
As stated in the introduction, until now the cost-
effectiveness of rituximab was assessed only in health care 
settings of economically more developed countries, such as 
the US,10 the UK,11 and Spain.9 While all studies used three-
stage models, the perspectives, model durations, and data 
extraction approaches differed. Methodological differences 
and non-generalizability of data limited transferring results 
of these studies to Ukraine. The third-party perspective is 
not applicable for Ukraine and, because of the significant 
number of assumptions,10 the societal perspective also is not 
considered. Additionally, the use of parametric extrapolation 
methods for survival analysis instead of raw trial data was 
considered important because of the high impact of survival 
parameters on the ICER. While no relation between the 
country’s income expressed by GDP per capita and the cost-
effectiveness of FCR in comparison to FC has been shown 
in prior research,9–11 in our study we see a significant differ-
ence in the values of the ratios observed. We also note an 
important similarity between our study and one conducted in 
the Spanish health care setting;9 namely, treating treatment-
naïve patients with FCR appeared to be more cost-effective 
than for refractory/relapsed patients.
limitations
As a limitation we should point out that data pertaining to 
the trial population and the mortality rate from non-CLL 
causes among trial populations were not available, thus 
may not correspond to the Ukrainian population. Moreover, 
Ukrainian costs data are limited and based on one study 
assessment.
Conclusion
State coverage of rituximab treatment may not be considered 
a cost-effective treatment option for the Ukrainian popula-
tion compared to current care; however, it may become 
 cost-effective under conditions of economic stability, cost-
effectiveness threshold growth or rituximab price negotia-
tions. Taking into account the WHO recommendations on 
cost-effectiveness thresholds and current GDP per capita in 
Ukraine, state coverage of FCR for treatment-naïve patients 
is more economically argued than that for refractory/relapsed 
patients.
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